

Salvatore Petta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2788809/salvatore-petta-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

254
papers

10,355
citations

55
h-index

94
g-index

317
ext. papers

13,937
ext. citations

5
avg, IF

6.18
L-index

#	Paper	IF	Citations
254	PSD3 downregulation confers protection against fatty liver disease.. <i>Nature Metabolism</i> , 2022 , 4, 60-75	14.6	1
253	P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i236-i236	1.5	
252	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	2
251	Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial.. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022 ,	4.5	1
250	Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators.. <i>JHEP Reports</i> , 2022 , 4, 100444	10.3	0
249	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022 , 5, 61-90	0.3	0
248	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , 2022 , 11, 75-84	9.1	4
247	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
246	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2
245	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022 , 101925	2.4	0
244	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
243	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021 , 53, 1301-1307	3.3	2
242	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021 , 53, 1603-1609	3.3	
241	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021 , 160, 1634-1646.e7	13.3	23
240	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1190-1199	3.4	3
239	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , 2021 , 8, 2004168	13.6	5
238	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	31

237	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2389-2396	4	3
236	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021 , 53, 677-681	3.3	7
235	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). <i>Digestive and Liver Disease</i> , 2021 , 53 Suppl 2, S49-S86	3.3	2
234	Ultra-processed food is associated with features of metabolic syndrome and non-alcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 2635-2645	7.9	6
233	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2345-2353	4.5	17
232	Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. <i>Ultrasonography</i> , 2021 , 40, 407-416	4.3	5
231	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021 , 41, 2228-2232	7.9	4
230	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 777-787.e17	6.9	6
229	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 806-815.e5	6.9	21
228	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
227	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021 , 41, 321-332	7.9	10
226	The Role of Transient Elastography in NAFLD 2021 , 61-74		
225	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2021 ,	19.2	27
224	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 2712-2719	7.9	3
223	Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5112-5125	5.6	1
222	Is there an 'ideal' diet for patients with NAFLD?. <i>European Journal of Clinical Investigation</i> , 2021 , e13659	4.6	2
221	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. <i>Journal of Hepatology</i> , 2021 , 75, 659-689	13.4	102
220	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1979-1981	6.9	4

219	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
218	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 786-794	13.4	21
217	Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance. <i>Journal of Hepatology</i> , 2020 , 73, S625-S626	13.4	
216	Genetic variants in the MTHFR are not associated with fatty liver disease. <i>Liver International</i> , 2020 , 40, 1934-1940	7.9	1
215	Extrahepatic Manifestations of Chronic Viral C Hepatitis. <i>Gastroenterology Clinics of North America</i> , 2020 , 49, 347-360	4.4	8
214	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1014-1022	4.5	4
213	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020 , 40, 1545-1555	7.9	19
212	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020 , 71, e694-e701	11.6	9
211	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 235-245	1.4	9
210	Non-invasive Diagnostic Approach to NASH: Biological Markers 2020 , 235-256		
209	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020 , 130, 975-985	1.9	3
208	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. <i>Current Pharmaceutical Design</i> , 2020 , 26, 1110-1118	3.3	3
207	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3928-3938	3.3	2
206	Biochemical Biomarkers of NAFLD/NASH 2020 , 89-114		1
205	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020 , 15, e0243590	3.7	0
204	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020 , 296, 40-47	3.1	36
203	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. <i>HIV Medicine</i> , 2020 , 21, 96-108	2.7	6
202	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020 , 40, 530-538	7.9	1

201	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020 , 71, 1953-1966	11.2	27
200	Outcomes of Liver Transplant for Adults With Wilson's Disease. <i>Liver Transplantation</i> , 2020 , 26, 507-516	4.5	7
199	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. <i>Digestive and Liver Disease</i> , 2020 , 52, 359-367	3.3	2
198	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2810-2817	11.6	7
197	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
196	P162 Prevalence of nafld (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S219-S220	1.5	0
195	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020 , 1865, 158765	5	4
194	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020 , 40, 2820-2827	7.9	9
193	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
192	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2408-2418	6.7	28
191	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 2103-2110	4.5	3
190	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020 , 52, 937-941	3.3	22
189	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020 , 73, S13-S14	13.4	3
188	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 517-519	6.9	8
187	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 935-944.e3	6.9	55
186	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
185	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020 , 71, 1213-1227	12.7	104
184	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113

183	Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study). <i>Liver International</i> , 2019 , 39, 2240-2243	7.9	3
182	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019 , 1, 188-198	10.3	46
181	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Liver International</i> , 2019 , 39, 1742-1754	7.9	37
180	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2019 , 10, 604	5.6	10
179	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2019 , 51, e26	3.3	3
178	gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <i>Journal of Lipid Research</i> , 2019 , 60, 1144-1153	6.3	27
177	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42
176	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 1325-1334	7.9	23
175	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2310-2319.e6	6.9	42
174	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019 , 71, 265-273	13.4	80
173	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	12
172	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
171	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019 , 114, 916-928	0.7	27
170	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 22-27	1.8	181
169	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 54-64.e1	6.9	31
168	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019 , 47, 141-168	5.8	
167	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018 , 69, 18-24	13.4	68
166	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. <i>Liver International</i> , 2018 , 38, 2060-2068	7.9	39

165	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. <i>Digestive and Liver Disease</i> , 2018 , 50, 58	3.3	
164	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018 , 155, 411-421.e4	13.3	201
163	Is global elimination of HCV realistic?. <i>Liver International</i> , 2018 , 38 Suppl 1, 40-46	7.9	30
162	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. <i>Journal of Internal Medicine</i> , 2018 , 283, 356-370	10.8	140
161	Can we prevent and modify cardiometabolic disorders by controlling HCV infection?. <i>Gut</i> , 2018 , 67, 403-404	10.4	
160	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018 , 38, 715-723	7.9	15
159	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. <i>Cardiovascular Diabetology</i> , 2018 , 17, 28	8.7	22
158	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 740-749	6.1	12
157	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
156	Liver and Statins: A Critical Appraisal of the Evidence. <i>Current Medicinal Chemistry</i> , 2018 , 25, 5835-5846	4.3	12
155	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018 , 11,	5.2	26
154	Expert opinion on managing chronic HCV in patients with cardiovascular disease. <i>Antiviral Therapy</i> , 2018 , 23, 35-46	1.6	5
153	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018 , 13, 1139-1151	3.7	2
152	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018 , 13, 1139-1151	4.8	3
151	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> , 2018 , 50, 1133-1152	3.3	2
150	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018 , 69, 1155-1163	13.4	25
149	Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2018 , 69, 1203-1204	13.4	
148	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018 , 2, 666-675	6	30

147	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018 , 69, 878-885	13.4	75
146	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
145	A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 564-573	6.1	8
144	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017 , 65, 1840-1850	11.2	51
143	Reply. <i>Hepatology</i> , 2017 , 65, 2128	11.2	
142	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 1157-1166	7.9	53
141	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017 , 49, 471-483	3.3	179
140	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 65-71	13.4	63
139	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017 , 37, 1389-1396	7.9	26
138	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
137	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2660-2669	5.6	30
136	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017 , 67, 577-584	13.4	80
135	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1604-1611.e1	6.9	83
134	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017 , 49, e60	3.3	3
133	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017 , 49, e59	3.3	2
132	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 510-518	6.1	111
131	Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. <i>PLoS ONE</i> , 2017 , 12, e0186136	3.7	38
130	Evidence-Based Medicine and the Problem of Healthy Volunteers. <i>Annals of Hepatology</i> , 2017 , 16, 832-834	3.4	4

129	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2017 ,	13.4	9
128	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
127	Interferon lambda 4 rs368234815 TT>T variant is associated with liver damage in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017 , 66, 1885-1893	11.2	59
126	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
125	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 617-627	6.1	94
124	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 688-695	6.1	104
123	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
122	Hepatitis C virus and cardiovascular: A review. <i>Journal of Advanced Research</i> , 2017 , 8, 161-168	13	23
121	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 160-168	6.1	58
120	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
119	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017 , 65, 1145-1155	11.2	135
118	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017 , 12, e0185728	3.7	28
117	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3	12
116	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. <i>Genes and Immunity</i> , 2016 , 17, 328-34	4.4	8
115	Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'. <i>Journal of Hepatology</i> , 2016 , 64, 984-5	13.4	1
114	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2016 , 48, e7-e8	3.3	2
113	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. <i>Hepatology</i> , 2016 , 63, 2032-43	11.2	183
112	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 739-50	5.1	12

111	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 682-90	13.4	79
110	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. <i>Gastroenterology</i> , 2016 , 150, 1219-1230.e6	13.3	347
109	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
108	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016 , 150, 145-155.e4; quiz e15-6	13.3	156
107	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016 , 16, 721-737	2.5	12
106	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	88
105	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0163069	3.7	45
104	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2016 , 95, e3446	1.8	25
103	Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. <i>Liver International</i> , 2016 , 36, 1765-1773	7.9	14
102	Reply. <i>Hepatology</i> , 2016 , 63, 1394	11.2	
101	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. <i>Hepatology</i> , 2016 , 63, 787-98	11.2	70
100	Reply. <i>Hepatology</i> , 2016 , 64, 701	11.2	
99	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016 , 36, 198-204	7.9	12
98	The cheating liver: imaging of focal steatosis and fatty sparing. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 671-8	4.2	19
97	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015 , 61, 506-14	11.2	311
96	The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 193-200	5.6	21
95	The UCP2 -866G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , 2015 , 35, 1574-80	7.9	35
94	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 939-48	6.1	16

93	Response to Dr. Sertoglu and colleagues. <i>Liver International</i> , 2015 , 35, 285-6	7.9	
92	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 1037-46	4.1	42
91	Recurrence of hepatocellular carcinoma after liver transplantation: an update. <i>Future Oncology</i> , 2015 , 11, 2923-36	3.6	37
90	Reply: To PMID 24691835. <i>Hepatology</i> , 2015 , 61, 1097	11.2	1
89	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015 , 62, 928-33	13.4	115
88	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015 , 35, 1566-73	7.9	94
87	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. <i>Digestive Diseases</i> , 2015 , 33, 668-74	3.2	9
86	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015 , 62, 1101-10	11.2	131
85	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11088-111	5.6	59
84	Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2015 , 10, e0142210	3.7	24
83	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , 2015 , 2015, 431750	3.4	13
82	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , 2015 , 63, 705-12	3.4	227
81	Epicardial fat in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015 , 62, 1215	13.4	3
80	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , 2015 , 82, 48-52	3.6	8
79	Current and future HCV therapy: do we still need other anti-HCV drugs?. <i>Liver International</i> , 2015 , 35 Suppl 1, 4-10	7.9	23
78	Reply: To PMID 25251399. <i>Hepatology</i> , 2015 , 62, 660	11.2	6
77	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014 , 59, 1692-705	11.2	64
76	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 936-42	3.3	14

75	Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?". <i>Journal of Hepatology</i> , 2014 , 61, 173-5	13.4	
74	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). <i>Digestive and Liver Disease</i> , 2014 , 46, 18-24	3.3	9
73	Cardiovascular diseases and HCV infection: a simple association or more?. <i>Gut</i> , 2014 , 63, 369-75	19.2	60
72	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". <i>Journal of Hepatology</i> , 2014 , 60, 677-8	13.4	1
71	Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 878-884.e1	6.9	10
70	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014 , 61, 523-9	13.4	57
69	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e87523	3.7	83
68	Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16726-33	5.6	2
67	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013 , 59, 1169-76	13.4	28
66	Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 311-7.e1	6.9	27
65	Reply: To PMID 22135089. <i>Hepatology</i> , 2013 , 57, 422	11.2	
64	Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients". <i>Journal of Hepatology</i> , 2013 , 58, 403-4	13.4	3
63	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2013 , 58, 771-7	13.4	52
62	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 174-82	3.4	10
61	How to optimize HCV therapy in genotype 1 patients: predictors of response. <i>Liver International</i> , 2013 , 33 Suppl 1, 23-9	7.9	19
60	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 658-66	13.4	34
59	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 486-93	3.4	42
58	Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E304-8	5.6	48

57	Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. <i>Hepatitis Monthly</i> , 2013 , 13, e7176	1.8	10
56	Metabolic factors and chronic hepatitis C: a complex interplay. <i>BioMed Research International</i> , 2013 , 2013, 564645	3	23
55	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013 , 57, 1046-54	11.2	78
54	NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. <i>PLoS ONE</i> , 2013 , 8, e68364	3.7	20
53	PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2013 , 8, e74089	3.7	47
52	Chemoprevention for hepatocellular carcinoma: the role of statins. <i>Hepatobiliary Surgery and Nutrition</i> , 2013 , 2, 1-3	2.1	
51	Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5193-5218	3.3	11
50	Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5193-218	3.3	3
49	Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5297-313	3.3	10
48	Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 465-72	3.4	8
47	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. <i>Liver International</i> , 2012 , 32, 1443-50	7.9	15
46	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012 , 56, 1356-62	13.4	72
45	Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. <i>Gastroenterology</i> , 2012 , 143, 1253-1260.e4	13.3	471
44	Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. <i>Digestive and Liver Disease</i> , 2012 , 44, 245-50	3.3	9
43	Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?. <i>BMC Infectious Diseases</i> , 2012 , 12 Suppl 2, S3	4	9
42	Reproductive status is associated with the severity of fibrosis in women with hepatitis C. <i>PLoS ONE</i> , 2012 , 7, e44624	3.7	46
41	Serum γ -glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. <i>PLoS ONE</i> , 2012 , 7, e51165	3.7	24
40	Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. <i>Frontiers in Bioscience - Elite</i> , 2012 , 4, 1276-86	1.6	7

39	Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. <i>Hepatology</i> , 2012 , 55, 1317-23	11.2	105
38	Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?. <i>Hepatology</i> , 2012 , 55, 1309; author reply 1309-10	11.2	1
37	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012 , 56, 850-60	11.2	91
36	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 238-47	6.1	74
35	Visceral adiposity index and exercise in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 490-490	6.1	0
34	Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. <i>Antiviral Therapy</i> , 2012 , 17, 111-8	1.6	8
33	Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , 2012 , 17, 823-31	1.6	28
32	Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. <i>Gastroenterology</i> , 2011 , 140, 818-29	13.3	85
31	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011 , 43, 404-10	3.3	24
30	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2112-20	0.7	148
29	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 1350-60	6.1	104
28	Is liver stiffness measurement unreliable in obese patients? authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 255-256	6.1	
27	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 757-66	6.1	95
26	Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1043-1044	6.1	
25	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e372-80	3.4	17
24	Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. <i>Liver International</i> , 2011 , 31 Suppl 1, 36-44	7.9	8
23	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011 , 31, 507-15	7.9	58
22	Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. <i>Current Pharmaceutical Design</i> , 2010 , 16, 741-52	3.3	52

21	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2010 , 51, 1158-67	11.2	318
20	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. <i>Hepatology</i> , 2010 , 51, 1858-1858.2		
19	Reply:. <i>Hepatology</i> , 2010 , 51, 2230-2230	11.2	
18	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010 , 52, 1543-52	11.2	76
17	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009 , 49, 195-203	11.2	56
16	Reply:. <i>Hepatology</i> , 2009 , 49, 1394-1395	11.2	
15	Reply:. <i>Hepatology</i> , 2009 , 49, 1776-1776	11.2	
14	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 603-13	6.1	20
13	Serum BLYS/BAFF predicts the outcome of acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 397-405	3.4	15
12	Non-alcoholic fatty liver disease pathogenesis: the present and the future. <i>Digestive and Liver Disease</i> , 2009 , 41, 615-25	3.3	190
11	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 293-308	5.5	54
10	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009 , 14, 631-9	1.6	5
9	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009 , 14, 631-639	1.6	18
8	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 523-30	3.4	15
7	Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome. <i>Digestive and Liver Disease</i> , 2008 , 40, A1-A2	3.3	
6	Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1136-44	0.7	149
5	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008 , 48, 28-37	11.2	49
4	Reply:. <i>Hepatology</i> , 2008 , 48, 1725-1726	11.2	

3	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1181-91	6.1	59
2	Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2472-7	0.7	48
1	Genotype 1 Relapsers and Non-Responders84-89		